Inovio Flags $36.7M in Preliminary Q2 Cash as Liquidity Fears Mount
INO is trading near its 52-week low of $0.95 (13% below the low).
Summary
Inovio disclosed a preliminary Q2 2026 cash balance of $36.7 million, a key liquidity metric for the struggling biotech. The update arrives alongside a concurrent public offering, highlighting the company's urgent need for capital.
Key Events · Earnings and Guidance · INO
-
Preliminary Q2 Cash Balance
Based on preliminary unaudited figures, Inovio estimates cash and cash equivalents of approximately $36.7 million as of June 30, 2026.
-
Liquidity Context
The cash balance is disclosed against a backdrop of severe liquidity concerns, a recent $300 million shelf registration, and a concurrent public offering announced today.
-
Financial Reporting Caveat
The estimate is subject to completion of quarter-end closing procedures and has not been reviewed by the company's auditor, Ernst & Young LLP.
Analysis · INO · Life Sciences
A preliminary cash balance of $36.7 million as of June 30, 2026, was disclosed by Inovio, a critical update given the company's severe liquidity issues and recent $300 million shelf registration. While the cash position offers some runway, it remains precarious for a pre-revenue biotech facing ongoing FDA skepticism and securities lawsuits. The disclosure coincides with a concurrent public offering, signaling an active push to raise capital and extend the runway.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.6M. The 52-week trading range was $0.95 to $2.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.